NCT00282386View on ClinicalTrials.gov

A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)

PHASE3CompletedINTERVENTIONAL

Enrollment

2,586

Participants

Timeline

Start Date

December 23, 1999

Primary Completion Date

September 1, 2004

Study Completion Date

September 1, 2004

Conditions

Colorectal Adenoma

Interventions

DRUG

MK0966; Rofecoxib / Duration of Treatment: 156 weeks

DRUG

Placebo/ Duration of Treatment: 156 weeks

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY